Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells.
A. Letian, E. Y. Lemma, P. Cavaliere, N. Dephoure, N. K. Altorki, T. E. McGraw
The paper uses proximity proteome mapping to show that anti-PD-L1 therapy disrupts specific PD-L1-dependent pathways in EGFR-mutant lung cancer cells, leading to altered cell migration and EGFR stability.
bioRxiv · Sep 17, 2021 · PreprintCancer Biology